Small Silver Lining for Life Sciences Sector
It’s tough times for older VC-backed drug companies, with a closed IPO market and dwindling cash reserves. But there is a small bit of good news today, which might encourage some existing shareholders to keep fishing instead of cutting bait. According to In Vivo Blog, the FDA appears poised to make 2008 the best year for new drug approvals since 2004. Twenty new molecules have gotten the a-ok so far, and eight more applications could be acted
21 November 2008•1 min read
